BUSINESS
Zydus’ COVID-19 vaccine shows 66.6% efficacy in Phase-3 interim analysis, company files for emergency use
No moderate case of COVID-19 disease was observed in the vaccine arm post administration of the third dose suggesting 100% efficacy for moderate disease. No severe cases or deaths due to COVID-19 occurred in the vaccine arm after administration of the second dose of the vaccine.
BUSINESS
Here is what five experts are saying on 'mix and match' of COVID-19 vaccines
There are some studies mostly conducted in Europe that show that if you use Oxford-AstraZeneca vaccine followed by Pfizer-BioNTech vaccine - that there is increase in reactogencity and the antibody response is little higher- which is good, says one of the experts.
BUSINESS
Bharat Biotech says hasn't got advance payment nor supplied jabs to Brazil
Bharat Biotech was responding to reports in media about the allegations of graft surrounding the $324-million Covaxin contract signed by Brazil, which has since been suspended by that country.
BUSINESS
USFDA warning letter to Lupin on Somerset facility cites repeated GMP violations at manufacturing network
"Repeated violations at multiple sites demonstrate your company’s corporate oversight and control over the manufacture of drugs is inadequate," the USFDA said in the letter addressed to Vinita Gupta, CEO of Lupin
BUSINESS
Cipla says doesn't have definitive pact on commercial supplies of Moderna vaccine
Cipla said it is supporting Moderna with the regulatory approval and importation of vaccines to be donated to India. The government of India has issued a registration certificate and a permission to import the COVID-19 Vaccine Moderna for restricted use in an emergency situation, in adults aged 18 years and older.
BUSINESS
COVID-19 vaccine | Serum Institute applied for marketing approval of Covishield jab in Europe: Sources
The information contrasts with the European Medicines Agency statement on June 29 which clarifies that it hasn't received any request for marketing authorisation of Covishield.
BUSINESS
What you need to know about mixing and matching of different COVID-19 vaccines
UK study shows that mixed schedules of AstraZeneca and Pfizer jabs, when given at a four-week interval, induced an immune response that is above the AstraZeneca vaccine. Side-effects, such as chills, headaches and muscle pain, were short-lived in volunteers who received a mixed schedule.
BUSINESS
Sun Pharma, Cipla and others partner to conduct trials of COVID-19 antiviral drug Molnupiravir
As per the directive of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization, Dr.Reddy’s will conduct the clinical trial using its product, and the other four pharma companies will be required to demonstrate equivalence of their product to the product used by Dr. Reddy’s in its clinical trial.
BUSINESS
Dishman Carbogen Amcis expects turnaround in FY22, working on resolution of regulatory issues at Bavla site
The European Directorate for the Quality of Medicines and Healthcare rates the corrective actions taken by the company on certain quality issues as appropriate. The European body had inspected the company’s Bavla site in February 2020.
BUSINESS
Dr Reddy's says 'slight' delay in commercial rollout of Sputnik V vaccine
The delay is "due to dependency on imported consignments, and quality testing in India", the company has said.
BUSINESS
Loan guarantee scheme to boost medical infra, but simplified approvals need of the hour, says private providers
The Finance Minsiter Nirmala Sitharaman said the interest rate offered on the loan guarantee scheme is capped at 7.95 percent. Currently most private hospitals borrow at 12-14 percent interest rates. But executives of hospitals felt that the interest rates can be further cut by 200 basis points to make it more compelling to go beyond metro cities.
BUSINESS
Medical tourism to get boost with Centre's 5 lakh free tourist visa scheme, say experts
According to government, around 10.93 million foreign tourists visited India in 2019, spent about $30.098 billion on leisure, business and medical treatment.
BUSINESS
IPO-bound PharmEasy buys Thyrocare; is it worth the price and what does this mean for diagnostic sector?
Several analysts and competitors Moneycontrol spoke to said that the deal would be a win-win for PharmEasy and shareholders of Thyrocare and more importantly for Velumani, the Chairman of Thyrocare, who will be cashing out.
BUSINESS
Serum Institute of India begun manufacturing of Novavax vaccine early this week
"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing," Poonawalla said it a tweet.
BUSINESS
Piramal Enterprises looking at acquisition of multiple pharma assets, possible re-entry into domestic formulations
Acquisitions of niche manufacturing capabilities for a Contract Development and Manufacturing Organisation, hospital generics business to sell specialised products in over 100 countries, and organic and inorganic addition of healthcare products among targets.
BUSINESS
Exclusive: KKR-controlled drug maker JBCPL evaluating acquistion of select brands, mid-sized firm
KKR's deep pockets and expertise is expected to help JBCPL to expand quickly using both organic and inorganic options. KKR bought a controlling stake in the Mumbai-based family-owned drug maker JBCPL a year ago for Rs 3,100 crore.
BUSINESS
Apollo Hospitals creates India's largest omni-channel health platform, reports Rs 170 crore net profit for Q4FY21
As per the reorganisation, Apollo has transferred its back-end offline pharmacy business (excluding hospital-based pharmacies), digital healthcare platform Apollo 24/7, its investment in retail pharmacy business (Apollo Medicals Private Ltd), and the "Apollo 24/7" brand, the "Apollo Pharmacy" brand and private label brands into the healthcare group's 100 percent subsidiary Apollo HealthCo Limited.
BUSINESS
Pfizer CEO Albert Bourla says in final stages of reaching COVID-19 vaccine supply agreement with Indian govt
Bourla said that Pfizer will be able to produce 3 billion vaccines by the end of 2021, and 4 billion vaccines in 2022.
BUSINESS
Pfizer says won’t make exception for India in its global approach for vaccine supply
Foreign vaccine suppliers want protection from potential lawsuits against adverse side effects, but analysts say India is in a better position to bargain now that the second wave is receding, domestic supply is rising and new vaccines are hitting the market
BUSINESS
Explained | What Phase 3 data submission of Covaxin means, how close is it to WHO approval, and comparison with other jabs
The Phase-3 trials for the vaccine were conducted on 25,800 volunteers. Bharat Biotech has submitted the Phase-3 efficacy data earlier this week. Covaxin, the country’s first indigenous COVID-19 vaccine, was developed with seed strains received from the National Institute of Virology.
BUSINESS
Dr Reddy's launches generic version of triglyceride lowering drug Vascepa in US
Dr Reddy's said its generic Vascepa was not indicated for other cardiovascular risk conditions like myocardial infarction, stroke, coronary revascularisation, and unstable angina, limiting the scope of its sales.
BUSINESS
Sun Pharma enters patent litigation settlement with Celgene for launch of generic Revlimid
As per the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantities of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.
BUSINESS
Exclusive | SII focused on local vaccine demand, may export Covishield towards year end
Company risks facing litigation for delaying delivery of vaccines to COVAX Facility, set up to procure and distribute shots in poor countries.
BUSINESS
Zydus, Bayer decide to extend their joint venture in India by three more years
The joint venture will continue to operate in therapies including cardiology, diabetes, women’s health, ophthalmology and oncology, with new products in the pipeline, the companies said in a statement.
